Stay updated on ARV-471 & Palbociclib in ER+/HER2- mBC Clinical Trial

Sign up to get notified when there's something new on the ARV-471 & Palbociclib in ER+/HER2- mBC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ARV-471 & Palbociclib in ER+/HER2- mBC Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    Revision label updated from v3.5.3 to v3.5.4, indicating a new release of the page. This reflects an internal deployment that may include fixes or enhancements to the page’s presentation or underlying systems.
    Difference
    0.0%
    Check dated 2026-05-15T15:20:28.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    20 days ago
    No Change Detected
  4. Check
    27 days ago
    Change Detected
    Summary
    The page’s revision/version label was updated from v3.5.2 to v3.5.3, reflecting a website/system update rather than a change to the study record content.
    Difference
    0.0%
    Check dated 2026-04-24T05:53:13.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    The study status is updated to Completed with new dates (2026-04-15; 2026-03-05; 2026-04-07; 2026-04) and revision v3.5.2, and the previous Active, not recruiting status along with its earlier dates and revision v3.5.0 were removed.
    Difference
    0.4%
    Check dated 2026-04-17T02:36:36.000Z thumbnail image
  6. Check
    63 days ago
    Change Detected
    Summary
    Site revision tag updated to Revision: v3.5.0, replacing Revision: v3.4.3.
    Difference
    0.0%
    Check dated 2026-03-19T05:11:57.000Z thumbnail image
  7. Check
    70 days ago
    Change Detected
    Summary
    Revision updated to v3.4.3, replacing v3.4.2.
    Difference
    0.0%
    Check dated 2026-03-12T02:49:30.000Z thumbnail image
  8. Check
    98 days ago
    Change Detected
    Summary
    Updated study details add a core biopsy requirement for ER IHC and PD testing, and introduce dose escalation with an RP2D plus a palbociclib combination cohort. ARV-471 dosing for Parts A and B is now specified as QD or BID for 28-day cycles, with pharmacokinetic endpoints (AUC) included.
    Difference
    0.8%
    Check dated 2026-02-11T14:15:53.000Z thumbnail image

Stay in the know with updates to ARV-471 & Palbociclib in ER+/HER2- mBC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ARV-471 & Palbociclib in ER+/HER2- mBC Clinical Trial page.